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Objective: To study the effects of treatment with atypical antipsychotic drugs on brain levels 
of glutamate plus glutamine in early-stage first-episode schizophrenia.
Participants: Sixteen patients (eight males, eight females; aged 30 ± 11 years) completed 
the study.
Methods: We used administered 6 months of atypical antipsychotic drugs and used proton 
magnetic resonance spectroscopy to evaluate the results.
Results: We found that the administration of atypical antipsychotic drugs for 6 months decreased 
the glutamate plus glutamine/creatine ratio in the frontal lobe. These results suggest that the 
administration of atypical antipsychotic drugs for at least 6 months decreased glutamatergic 
neurotransmissions in the frontal lobe in early-stage first-episode schizophrenia, but there was no 
difference in frontal-lobe levels between patients and control subjects before administration.
Conclusion: Taking these findings into account, the glutamatergic and GABAergic neurons 
are implicated in early-stage first-episode schizophrenia, but in complex ways.
Keywords: Proton magnetic resonance spectroscopy, creatine, frontal lobe, parieto-occipital 
node, left basal ganglia
Introduction
Glutamate’s role in schizophrenia has been investigated in recent years. Abnormal 
glutamatergic neurotransmission has been reported in human postmortem studies. 
Proton magnetic resonance spectroscopy (MRS) allows us to examine brain glutamate 
and glutamine in vivo. Tibbo et al1 reported that the glutamate system might play a 
role in neuroarchitectural abnormalities seen in schizophrenia and that higher-than-
normal glutamatergic metabolites at the early stages of schizophrenia might lead to 
excitotoxicity, which decreases in the chronic state. Olbrich et al2 also demonstrated 
that glutamate levels were significantly higher in the left dorsolateral prefrontal cor-
tex in patients with first-episode schizophrenia. In contrast, no difference was found 
in glutamate plus glutamine between schizophrenia patients and controls in other 
regions.3,4 Taking these findings into account, brain glutamate levels in schizophrenia 
seem inconsistent and controversial. The aim of the present study was to investigate 
the brain levels of glutamate plus glutamine in early-stage first-episode schizophre-
nia patients. Another aim was to examine the influence of atypical antipsychotic 
treatment on brain levels of glutamate plus glutamine in the patients. Therefore, we 
investigated the effects of treatment with atypical antipsychotic drugs for 6 months Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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on brain levels of glutamate plus glutamine in the frontal 
lobe, left basal ganglia, and the parieto-occipital lobe in 
early-stage first-episode   schizophrenia patients treated with 
atypical antipsychotics.
Methods
subjects
A total of 23 patients who fulfilled DSM-IV-TR criteria 
A, B, D, E, and F, but who were within 6 months of dis-
ease onset, were recruited for the study, and all underwent 
MRS evaluation. After 6 months of follow-up, a diagnosis 
of schizophrenia was established in 20 of 23 patients. Two 
patients were excluded from the study, one because of the 
difficulty of performing MRS given his mental condition, and 
the other because the image quality was impaired by severe 
artifacts from dental materials. Thus, 18 patients (nine males, 
nine females; aged 31 ± 12 years) were finally enrolled in the 
study. All patients were screened using the Structured Clini-
cal Interview for DSM-IV disorders, and exclusion criteria 
for all groups included current or past serious medical or 
neurological illness or dependence on alcohol, or illicit sub-
stances. The patients’ psychopathology was assessed with the 
Positive and Negative Syndrome Scale (PANSS).5 Sixteen 
(eight males, eight females; 30 ± 11 years) of 18 patients 
were followed for 6 months. Eighteen healthy volunteers 
(nine males, nine females; age range 29 ± 11 years) with no 
current or past psychiatric history were also studied by MRS 
as sex- and age-matched controls. This study was approved 
by the Ethics Committee of the University of Occupational 
and Environmental Health. All participants gave written 
informed consent to participate in the study.
Mrs methodology
All subjects were examined between 4pm and 6pm, by 1H-MRS 
using a 3T MR system (Signa EXCITE 3T; GE Medical Sys-
tems, Waukesha, WI) with a standard quadrature head coil (GE 
Medical Systems). The regions of interest (ROIs) for 1H-MRS 
were set for the frontal lobe, the left basal ganglia, and the 
parieto-occipital lobe (ROI size = 3.0 cm × 3.0 cm × 3.0 cm)   
using two oriented images (axial image and sagittal image) for 
each region. We put a voxel in the frontal lobe, the left basal 
ganglia, and the parieto-occipital lobe. All of these ROIs were 
placed so as to avoid the lateral ventricle and skull.
We previously obtained brain gamma-aminobutyric acid 
(GABA) measurements in schizophrenic patients using a 
MEGA-PRESS sequence 9, and have reported that the reduc-
tions in the GABA concentrations were significantly greater in 
patients at the early stage of schizophrenia than in   controls.6 
By using a MEGA-PRESS sequence, the spectroscopic 
measurements of glutamate and glutamine in the same voxel 
could be obtained. Thus, in the present study, the glutamate 
and glutamine levels were acquired with the MEGA-PRESS 
sequence using the following parameters: repetition time (TR) 
3 seconds, echo time (TE) 68   milliseconds, and 128 averages. 
The total acquisition time for each PRESS spectrum was 
approximately 6 minutes. All spectra were analyzed by an LC 
model 12 using phantom-generated basis functions for the 
MEGA-edited spectra. The line width, signal-to-noise ratio, 
and baseline of each spectrum were checked to ensure the 
robustness of the data. Eddy-current correction was applied 
using an unsuppressed water spectrum at the appropriate echo 
time. The edited spectra were analyzed using LCM-basis 
functions that were generated from phantom measurements 
using the MEGA-PRESS sequence with the appropriate 
acquisition parameters.
statistical analysis
The unpaired t-test was used to compare differences in the 
glutamate plus glutamine/creatine (Cr) ratios between the 
schizophrenia group and the control group. Using nonpara-
metric Wilcoxon and Mann–Whitney tests we analyzed 
differences in glutamate plus glutamine before and after 
6 months’ treatment with atypical antipsychotic drugs. The 
level of significance was set at P , 0.05.
Results
There was no significant difference in age or gender 
between the healthy controls and the patient groups. The 
scores of positive (PANSS-P), negative (PANSS-N),   general 
  psychopathology (PANSS-G), and total (PANSS-T) in the 
early schizophrenia patients were 15.9 ± 4.2, 17.2 ± 5.3, 
34.2 ± 10.1, and 68.1 ± 17.0 (mean ± standard deviation), 
respectively. The ratios of glutamate plus glutamine/Cr in 
the left basal ganglia were significantly higher in the patients 
than in the controls (0.72 ± 0.16 vs 0.60 ± 0.18, z = −1.930, 
P = 0.0496), but no differences were found in the frontal 
lobe (0.7 9 ± 0.28 vs 0.67 ± 0.40, z = −1.226, P = 0.2057) 
or parieto-occipital lobe (0.71 ± 0.15 vs 0.74 ± 0.13, 
z = −0.142, P = 0.8868) (Figure 1). No associations were 
found between the glutamate plus glutamine/Cr ratios and 
positive, negative, and general psychopathology scores in 
PANSS. The administered atypical antipsychotic drugs and 
mean dosage were as follows: risperidone (n = 5), 2.9 mg; 
olanzapine (n = 5), 10.1 mg; aripiprazole (n = 4), 16.2 mg; 
and quetiapine (n = 2), 250 mg. The mean reduction of posi-
tive, negative, general psychopathology, and total scores of Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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PANSS after 6 months’ treatment with atypical antipsychotic 
drugs were 33.3, 26.3, 31.4, and 25.3%, respectively. Six 
months’ administration of atypical antipsychotic drugs 
reduced the glutamate plus glutamine/Cr ratio in the fron-
tal lobe (before, 0.78 ± 0.28; after 6 months, 0.57 ± 0.18: 
z = −2.792, P = 0.052), whereas, those in the left basal 
ganglia (before, 0.76 ± 0.15; after 6 months, 0.65 ± 0.19: 
z = −1.448, P = 0.1477), and parieto-occipital lobe (before, 
0.73 ± 0.19; after 6 months, 0.69 ± 0.11: z = −1.008, 
P = 0.3132) were not changed by the medication (Figure 2). 
No correlation was observed between the changes in any 
scores of PANSS and the changes in the glutamate plus 
glutamine/Cr ratios.
Discussion
We found that the glutamate plus glutamine/Cr ratio in the 
left basal ganglia was significantly higher in early-stage 
first-episode schizophrenia patients than in control subjects. 
No differences were observed in the frontal lobe and parieto-
occipital lobe between the two groups. Findings regarding 
glutamatergic metabolites in schizophrenia have been contro-
versial. Stanley et al7 and Ohrmann et al8 reported no change 
in prefrontal glutamate levels in treatment-naïve first-episode 
schizophrenia patients. Theberge et al9 found increased 
glutamine in the left anterior cingulate cortex and thalamus 
of treatment-naïve first-episode schizophrenia patients. The 
results in the present study were basically in accordance with 
the results of Stanley et al,7 Ohrmann et al,8 Bustillo et al,3 
and Reid et al.4 Recently, great attention has been paid to 
the basal ganglia, which is an important area of interaction 
between GABAergic and glutamatergic neurons.10,11 De la 
Fuente-Sandoval et al11 first reported that the glutamate/Cr 
ratio in the dorsal caudate nucleus was higher in drug-naïve 
schizophrenia patients than in control subjects. The present 
study’s findings of higher glutamate plus glutamine/Cr ratios 
in the left basal ganglia did not contradict those of De la 
Fuente-Sandoval et al.11 To the best of our knowledge, this 
is the first report demonstrating that treatment with atypi-
cal antipsychotic drugs for at least 6 months decreased the 
glutamate plus glutamine/Cr ratio in the frontal cortex in 
early-stage first-episode schizophrenia. However, no cor-
relation was observed between the changes in any scores 
in PANSS and the changes in glutamate plus glutamine/Cr. 
Theberge et al9 reported that brain glutamate and glutamine 
levels were significantly decreased in the anterior cingulate 
cortex, which belongs to the frontal lobe, in patients with 
chronic medicated schizophrenia. The authors speculated 
that the findings might indicate a decrease in the number of 
glutamatergic synapses in this region. On the other hand, we 
reported that the brain glutamate plus glutamine/Cr ratio was 
significantly increased, whereas GABA/Cr was significantly 
reduced in the left basal ganglia in patients with early-stage 
first-episode schizophrenia,6 and treatment with atypical 
antipsychotic drugs did not change brain GABA levels.12 
It has been reported that glutamatergic and GABAergic 
neurons might be disturbed in schizophrenia patients, and 
that these types of neurons interact.13 Taking these findings 
into account, glutamatergic neurotransmission might be dif-
ferent in different brain regions and the situation becomes 
more complicated depending on the stage of schizophrenia. 
Converging experimental and clinical evidence suggests 
that dysfunction of proper GABAergic inhibition and 
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Figure 2 The changes in Glx/cr before and 6 months after treatment with atypical 
antipsychotic drugs.
Note: *P , 0.05.
Abbreviations: Glx, glutamate plus glutamine; cr, creatine; F, frontal lobe; LB, left 
basal ganglia; O, parieto-occipital lobe; B, before treatment with atypical antipsychotic 
drugs; 6M, 6 months after treatment with atypical antipsychotic drugs.
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Figure 1 The ratios of Glx/cr in the three brain regions.
Note: *P , 0.05.
Abbreviations: Glx, glutamate plus glutamine; cr, creatine; F, frontal lobe; LB, left 
basal ganglia; O, parieto-occipital lobe; HC, healthy control; SC, early-stage first-
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  consequently imbalance between excitation and inhibition in 
the cerebral cortex underlies at least part of the pathophysi-
ological process of schizophrenia.14 The finding that the brain 
levels of glutamate plus glutamine at early-stage first-episode 
schizophrenia were significantly increased in the left basal 
ganglia, and subsequently decreased in the frontal lobe, but 
not in the left basal ganglia, suggests that the concentrations 
and changes in brain GABA and glutamate plus glutamine 
might vary in different brain regions. In future works, we will 
measure glutamate and glutamine separately, and in absolute 
amounts rather than as a Cr ratio, and also use drug-naïve 
schizophrenia patients as subjects.
Conclusion
In conclusion, it is possible that the administration of atypical 
antipsychotic drugs for at least 6 months decreased gluta-
matergic neurotransmissions in the frontal lobe in early-stage 
first-episode schizophrenia patients.
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